Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

EST Teva (TEVA) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Teva, a global pharmaceutical leader, to install the SaverOne System across its entire fleet of 50 delivery trucks in IsraelPetah Tikvah, Israel, ...

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...